Liquidia’s (LQDA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Liquidia (NASDAQ:LQDA) in a research note issued to investors on Thursday,Benzinga reports. They currently have a $29.00 price target on the stock. HC Wainwright also issued estimates for Liquidia’s Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.25) EPS and FY2029 earnings at $0.51 EPS.

LQDA has been the subject of several other research reports. Wells Fargo & Company initiated coverage on shares of Liquidia in a research note on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and set a $19.00 target price on shares of Liquidia in a research note on Thursday, January 9th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $26.63.

Liquidia Stock Down 2.1 %

NASDAQ:LQDA opened at $15.12 on Thursday. The company has a fifty day simple moving average of $14.79 and a two-hundred day simple moving average of $12.20. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -9.28 and a beta of 0.07. Liquidia has a 52 week low of $8.26 and a 52 week high of $16.92.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The business had revenue of $2.92 million during the quarter, compared to analyst estimates of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. On average, analysts expect that Liquidia will post -1.51 EPS for the current year.

Insider Buying and Selling

In related news, CEO Roger Jeffs sold 22,343 shares of the business’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $263,200.54. Following the completion of the sale, the chief executive officer now directly owns 1,019,177 shares of the company’s stock, valued at $12,005,905.06. The trade was a 2.15 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Rajeev Saggar sold 6,249 shares of the business’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $73,613.22. Following the completion of the sale, the insider now directly owns 270,388 shares of the company’s stock, valued at approximately $3,185,170.64. This trade represents a 2.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 71,245 shares of company stock worth $843,326. Corporate insiders own 30.10% of the company’s stock.

Institutional Investors Weigh In On Liquidia

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Corebridge Financial Inc. lifted its position in Liquidia by 2.3% in the fourth quarter. Corebridge Financial Inc. now owns 31,516 shares of the company’s stock valued at $371,000 after acquiring an additional 694 shares during the last quarter. Catalina Capital Group LLC lifted its position in Liquidia by 6.5% in the fourth quarter. Catalina Capital Group LLC now owns 18,307 shares of the company’s stock valued at $215,000 after acquiring an additional 1,125 shares during the last quarter. Cetera Investment Advisers lifted its position in Liquidia by 4.3% in the fourth quarter. Cetera Investment Advisers now owns 31,243 shares of the company’s stock valued at $367,000 after acquiring an additional 1,277 shares during the last quarter. Summit Investment Advisors Inc. lifted its position in Liquidia by 35.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock valued at $78,000 after acquiring an additional 1,719 shares during the last quarter. Finally, Sigma Planning Corp raised its holdings in shares of Liquidia by 3.4% in the fourth quarter. Sigma Planning Corp now owns 65,210 shares of the company’s stock valued at $767,000 after buying an additional 2,115 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).